<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Latent autoimmune <z:mp ids='MP_0002055'>diabetes</z:mp> in adults (LADA) is a disorder in which, despite the presence of islet antibodies at diagnosis of <z:mp ids='MP_0002055'>diabetes</z:mp>, the progression of autoimmune beta-cell failure is slow </plain></SENT>
<SENT sid="1" pm="."><plain>LADA patients are therefore not insulin requiring, at least during the first 6 months after diagnosis of <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="2" pm="."><plain>Among patients with phenotypic type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>, LADA occurs in 10% of individuals older than 35 years and in 25% below that age </plain></SENT>
<SENT sid="3" pm="."><plain>Prospective studies of beta-cell function show that LADA patients with multiple islet antibodies develop beta-cell failure within 5 years, whereas those with only GAD antibodies (GADAs) or only islet cell antibodies (ICAs) mostly develop beta-cell failure after 5 years </plain></SENT>
<SENT sid="4" pm="."><plain>Even though it may take up to 12 years until beta-cell failure occurs in some patients, impairments in the beta-cell response to intravenous <z:chebi fb="105" ids="17234">glucose</z:chebi> and glucagon can be detected at diagnosis of <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="5" pm="."><plain>Consequently, LADA is not a latent disease; therefore, autoimmune <z:mp ids='MP_0002055'>diabetes</z:mp> in adults with <z:hpo ids='HP_0003677'>slowly progressive</z:hpo> beta-cell failure might be a more adequate concept </plain></SENT>
<SENT sid="6" pm="."><plain>In agreement with proved impaired beta-cell function at diagnosis of <z:mp ids='MP_0002055'>diabetes</z:mp>, insulin is the treatment of choice </plain></SENT>
</text></document>